SKIN & AESTHETICS RESEARCH / MATRIX
Three Compounds, Three Different Risk Profiles
How a copper peptide, an untested three-peptide blend, and a melanocortin agonist differ in mechanism, evidence, and what is actually known.
The short version
This page lines up GHK-Cu, GLOW, and Melanotan II side by side. All three sit under one theme — skin, hair, and pigment research — but they work through different mechanisms and carry very different amounts of evidence.
GHK-Cu has the most human data and the only approved use, as a topical cosmetic ingredient. GLOW combines GHK-Cu with two other peptides but has never been tested as a blend. Melanotan II has old, small human trials and a long, serious case-report record.
Reading them together makes the differences clear: more evidence does not mean fewer safety concerns, and less regulation does not mean less mechanism. Each compound's profile stands on its own.
The comparison matrix
| Dimension | GHK-Cu | GLOW (research blend) | Melanotan II |
|---|---|---|---|
| Peptide class | Copper-binding tripeptide | Three-peptide combination (GHK-Cu + BPC-157 + TB-500) | Cyclic melanocortin receptor agonist |
| Most studied for | Collagen synthesis, wound healing, hair growth [1][3][4] | Not studied as a blend; parts studied for skin matrix and tissue repair [4][6][8][9][10] | Pigmentation and erectile function [11][14][15] |
| Evidence base | Small controlled human trials plus a large mechanistic literature [3][4][7] | Zero blend-level trials; single-component studies only [8][9] | Small trials from the late 1990s; recent case reports [15][11][13] |
| Regulatory status | Topical form (Copper Tripeptide-1) is a legal cosmetic ingredient; injectable/systemic use unapproved | Not an approved product; BPC-157 and TB-500 are unapproved research chemicals | Not approved anywhere; no completed Phase II or III trial |
| Key caution | Systemic/injectable use is unstudied in humans; possible copper accumulation with prolonged systemic use | TB-500 is WADA-prohibited at all times; the blend has no combined safety data [8] | New/changing moles, melanoma case reports, renal and priapism case reports [13] |
Mechanism
The three compounds act through unrelated biological pathways. GHK-Cu is a copper carrier and matrix-remodeling signal: at very low concentrations it drives skin fibroblasts to build collagen, elastin, and connective-tissue matrix, and its copper ion enables the cross-linking that makes new tissue stable [1][4][7]. GLOW layers GHK-Cu's matrix effect together with BPC-157's blood-vessel-growth and tissue-protective activity and TB-500's cell-migration activity — three separate mechanisms combined in one product, never in one study [8][10]. Melanotan II is structurally and functionally unrelated to either: it is a non-selective melanocortin receptor agonist that switches on pigment production in skin cells and appetite/arousal circuits in the brain, through a cAMP-driven signaling cascade [15]. Only GHK-Cu, and the GHK-Cu portion of GLOW, touch skin matrix biology directly; Melanotan II's route to 'aesthetics' runs entirely through pigment, not structure.
Evidence base
GHK-Cu carries the most complete human evidence of the three: a six-month, 45-person controlled hair-growth trial [3], decades of collagen-synthesis and wound-healing literature [4][6][7], and a 2025 review quantifying its anti-wrinkle efficacy against established comparators [1]. Much of that foundational work traces to a small number of research groups, which limits independent replication but does not erase the trial data.
GLOW has the thinnest direct evidence: no trial has tested the three-peptide combination at any dose. Every claim rests on BPC-157 [9][10], TB-500, or GHK-Cu [4][6] studied alone — a 2026 review is the only source that discusses all three peptides together, and even it evaluates them individually, not as a formulated blend [8].
Melanotan II has the oldest human trial data — a 1998 crossover study in 10 men [15] — but almost nothing since in controlled conditions. What has accumulated instead is a case-report literature: documented instances of renal injury, priapism, and melanoma in people who used it outside any trial [13].
Regulatory status
Regulatory standing tracks roughly with mechanism, not with how the products are marketed. Topical GHK-Cu — Copper Tripeptide-1 — is a legal cosmetic ingredient in the US, EU, and UK; injecting it or taking it systemically has no approved pathway anywhere. GLOW's components split three ways: GHK-Cu's topical form is a cosmetic ingredient, while BPC-157 and TB-500 are unapproved research chemicals with no therapeutic approval, and TB-500 (as the synthetic thymosin beta-4 fragment) is named on the World Anti-Doping Agency's Prohibited List at all times [8]. Melanotan II has never been approved by any regulator for any indication — no completed Phase II or III trial exists, and regulators in multiple countries have issued specific warnings against melanotan-containing tanning products [14].
Key caution
Each compound carries a defining caveat that should not be averaged away. For GHK-Cu, it is that the well-documented safety and efficacy record is topical-only — systemic and injectable use is unstudied, and repeated systemic copper exposure carries a theoretical accumulation concern. For GLOW, it is that the blend itself has no safety data: three peptides with different clearance rates, combined in one product, and one of them (TB-500) carries an anti-doping prohibition that has nothing to do with skin [8]. For Melanotan II, it is the growing case-report record of serious harm — new and changing moles, melanoma, renal infarction, and priapism — set against a product that was never approved and is sold without quality control [13]. Reading the three together, evidence volume and safety risk move independently, not together.